Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | 1 | 3 | — | — | — | 4 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 2 | — | — | — | 3 |
Hepatitis | D006505 | — | K75.9 | 1 | 2 | — | — | — | 3 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | 2 | — | — | — | 2 |
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Chronic hepatitis | D006521 | — | K73.9 | 1 | — | — | — | — | 1 |
Drug common name | SETROBUVIR |
INN | setrobuvir |
Description | Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.
|
Classification | Small molecule |
Drug class | antivirals: RNA polymerase (NS5B) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2 |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1076263 |
ChEBI ID | — |
PubChem CID | 66673837 |
DrugBank | — |
UNII ID | T5B2GI8F84 (ChemIDplus, GSRS) |